SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Onko BCG 50
Powder and solvent for suspension to administration to urinary bladder
BCG ad immunocurationem
BCG for immunotherapy
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Onko BCG 50
1 ampoule or 1 vial with the powder contains:
Live attenuated Bacillus Calmette-Guerin, Brazilian BCG Moreau substrain – 50 mg
1 ampoule or 1 vial of Onko BCG 50 contains no less than 150 mln of live BCG.
For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Powder and solvent for suspension to administration to urinary bladder.
White or off-white, dry, formless powder.
4. CLINICAL PARTICULARS
4.1. Therapeutic indications
The product is intended for use in treating superficial, epithelial non-invasive bladder tumours (carcinoma urotheliale Ta, Tis, T1).
The product should not be used in invasive bladder carcinoma, as chances for complete recovery are scarce.
Onko BCG 50 may be administered in recurring side effects (dysuria, increased body temperature) or increased size of induration (tuberculin reaction).
4.2. Posology and method of administration
One dose of Onko BCG 50, corresponding to 1 dose used for 1 intra-bladder infusion, comprises the content of 1 ampoule or 1 vial (50 mg) reconstituted in 1 ml of isotonic sodium chloride solution.
Method of administration
Add 1 ml of the solvent (sterile isotonic sodium chloride solution) to an ampoule or vial containing the powder, using a 5 ml sterile syringe. Carefully aspirate three times and release again ampoule or vial content, in order to obtain homogeneous suspension (avoid shaking and frothing the suspension). Next, collect the suspension from the ampoule or vial to a sterile 50 ml syringe and add 49 ml of sterile isotonic sodium chloride solution. After reconstitution, homogeneous suspension without visible conglomerates is obtained.
Using a 12-14F catheter inserted via urethra, remove urine from the bladder. Slowly introduce the entire portion of BCG suspension (50 ml) using the catheter and administer 5 ml of sterile sodium chloride solution, in order to completely remove BCG suspension from the catheter.
The patient should not drink any liquids for 3-4 hours prior to and 2 hours after administration of the product. Remove catheter after product is administered.
Administered BCG suspension must remain in the bladder for 2 hours; during that time, the patient should change his/her body position (on the stomach, on the back and on the sides) and after 2 hours, he/she shall void the bladder.
The suspension should be administered to the bladder not earlier than within 14 days after taking a biopsy specimen from the tumour or mucous membrane of the bladder or after transurethral resection of bladder tumour (TUR).
The procedure should be performed once a week, for six consecutive weeks, and followed by recommended maintenance treatment every 3 months, once a week for three consecutive weeks. In case of diagnosed tumour recurrence, the 6-week treatment should be repeated.
Before starting the treatment, intradermal tuberculin test (tuberculin sensitivity test, PPD test) should be given to a patient, in order to evaluate the degree of immune sensitivity of the patient. When induration is highly intense or when its diameter exceeds 1 cm (induration exceeding 6 mm in diameter is treated as positive reaction), planned immunotherapy should be abandoned. After completion of a 6-week treatment, intradermal tuberculin test should be repeated, in order to evaluate impact of the treatment on general immune sensitivity of the patient. In some patients, this sensitivity clearly increases.
Method of urination:
After 2 hours following drug administration, the patient should be recommended to urinate, and if there emerge problems with complete bladder voiding (urine retention after miction), the patient should be catheterized and retained urine should be removed. After urination, the lavatory is washed with typical disinfectants.
Hypersensitivity to an active ingredient or to any of the excipients listed in section 6.1.
The product should not be administered into the bladder in patients with:
– inborn or acquired defect of the immune system,
– treated with immunosuppressants (e.g. corticosteroids, cytostatic drugs or radio therapy),
– during pregnancy, lactation or in case of suspected pregnancy,
– urinary tract infection, until obtaining urine negative for microbes.
4.4. Special warnings and precautions for use
The product contains live attenuated Mycobacterium bovis bacilli, and therefore after completed procedure, all devices and materials (syringes, catheters etc.) should be disposed of in accordance with provisions regarding hazardous waste.
Sexual abstinence is recommended within 48 hours following administration of the product into the bladder. Use condoms within at least one week after the infusion.
The product cannot be used intravenously, subcutaneously and intramuscularly.
After product administration, an amount of liquid taken in within 24 hours after first urination should be increased. Within this time, at least 12 glasses of liquid should be taken in. Urinate regularly.
Lubricants used during catheter insertion should not contain tuberculostatics.
Prepare BCG suspension for administration into urinary bladder immediately before the procedure.
4.5. Interaction with other medicinal products and other forms of interaction
Do not use the product in patients simultaneously treated with cytostatic drugs and steroids administered systemically. Topical steroids are not contraindicated in treatment using the product.
During BCG treatment, administration of antibiotics with possible bactericidal effect on bacilli, acetylsalicylic acid (aspirin) derivatives and some antithrombotic drugs should be limited.
4.6. Pregnancy and lactation
The product should not be administered to pregnant women.
The product should not be administered to breastfeeding women.
4.7. Effects on ability to drive and use machines
Effects on ability to drive and use machines have not been investigated.
4.8. Undesirable effects
As in case of any other product, Onko BCG 50 may evoke side effects.
Treating of non-invasive bladder carcinoma with products administered into the bladder is well tolerated by majority of patients, however local or general adverse effects may be observed.
Lesions with tuberculous granulation tissue in the lungs have been observed.
The most common complication are symptoms of cystitis, usually emerging after second or third administration. Pollakiuria, haematuria, painful urgency observed on the day of product administration usually subside after a few hours.
More serious undesirable effects of the therapy have been known as well, such as tuberculous inflammation of inner layers of bladder walls, prostatitis and/or epididymitis with caseous necrosis lesions.
In patients with tuberculous prostatitis or maintained subfebrile body temperature, a 6-week treatment should be used, with daily administration of two drugs, 600 mg of rifampicin and 5 mg/kg b.w. of isoniazid.
In patients with acute septic symptoms and arthritis, a 4-month course of treatment adopted in treating urinary tuberculosis may be applied:
– daily over the period of 2 months, three drugs:
600 mg of rifampicin, 5 mg/kg b.w. of isoniazid
and 25 mg/kg b.w. of ethambutol (or 1500 mg of pyrazinamide)
– three times a week over the period of 2 consecutive months, two drugs:
600 mg of rifampicin and 10 mg/kg b.w. of isoniazid.
In case of arthritis symptoms, it may be necessary to include corticosteroids.
In patients with the aforementioned symptoms of generalized infection, treatment with the product must be absolutely abandoned.
In addition to topical reactions, general reactions may also appear, such as: ill-being, short-term increase in body temperature (38°C-39°C), chills, nausea, muscular and joint pain, diarrhoea, pain around sexual organs.
General symptoms are usually maintained for 1-3 days.
Very rarely, the aforementioned symptoms enforce discontinuation of the therapy and administration of tuberculostatic drugs.
Lesions with tuberculous granulation tissue have been observed in liver as well.
All more serious undesirable effects of intra-bladder administration of the product usually subside after four-month tuberculostatic chemotherapy.
After administration of Onko BCG 50, the following symptoms may appear:
– allergic reaction, possibly manifested in breathing difficulties, cough, rash, facial oedema,
– tuberculosis infection, possibly manifested in cough, high fever lasting more than 12 hours (temperature over 39.5°C) or fever lasting more than 2 days (temperature over 38.5°C),
– yellow eyes or yellow skin,
– greyish or whitish faeces,
– fever (temperature below 38.5°C) with chills, headache, muscular and joint pain lasting over 2 days,
– evident pain during urination or excessive urination,
In order to relieve side effect sensations, it is recommended to:
– stop smoking (if a patient is a tobacco smoker),
– get some rest when feeling fatigue,
– avoid drinking alcohol,
– follow all doctor’s recommendations and take drugs prescribed by the physician.
In case of administering an excessive dose or too long retention of the product in the bladder, rinse the bladder a number of times with sterile sodium chloride solution. Remove urine retained in the bladder using a catheter (in case of patients with residual urine) and provide tuberculostatics in case of emergence of septic symptoms.
5. PHARMACOLOGICAL PROPERTIES
5.1. Pharmacodynamic properties
Pharmacotherapeutic group: Immunostimulants, ATC code: L03AX
5.2. Pharmacokinetic properties
BCG has been applied as a non-specific immunostimulating factor in the treatment of some types of carcinoma.
Intra-bladder administration of BCG is intended to eliminate primary tumour or to delay or prevent its consecutive relapses. Specific mechanism of action of BCG has not been fully explained. It is believed, that the drug stimulates emergence of inflammation in the bladder wall which defends the organism against development of the disease, and stimulates the patient’s immune system.
5.3. Preclinical safety data
No human toxicity has been confirmed.
During tests on laboratory animals (guinea pigs and white mice), no toxicity has been confirmed.
6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Sodium chloride isotonic solution
No incompatibilities have been observed.
6.3. Expiry date
Use the product immediately after reconstitution.
6.4. Special precautions for storage
Store at 2°C-8°C (in refrigerator).
To protect the product from sunlight, store ampoules or vials in secondary packaging.
6.5. Nature and contents of container
50 mg of the powder in an ampoule or vial made of glass type I and 1.0 ml of the solvent in an ampoule made of glass type I in a cardboard box – 1 or 5 items per packaging.
Vial stopper is made of chloro butyl rubber or bromo butyl rubber with silicone layer.
6.6. Special precautions for disposal and other handling
BCG suspension for administration to urinary bladder should be prepared immediately before the procedure.
Activities related to performance of the procedure should be carried out in sterile conditions by personnel using sterile gloves, masks and caps. In case of polluting body or any item surfaces with BCG suspension, disinfect the affected site with 70% ethyl alcohol or 2% solution of septyl.
After finishing the procedure, dispose of the devices and materials in accordance with provisions regarding hazardous waste.
7. MARKETING AUTHORISATION HOLDER
“BIOMED-LUBLIN” Wytwórnia Surowic i Szczepionek Spółka Akcyjna
20-029 Lublin, ul. Uniwersytecka 10
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
30 July 1999 / 28 October 2004 / 4 February 2008 / 9 July 2013
10. DATE OF REVISION OF THE TEXT
18 January 2012